CLINICAL STUDY: MYOCARDIAL INFARCTION
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction
The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial
Sorin J. Brener, MD, FACC*,*,
Uwe Zeymer, MD, FACC ,
A. A. Jennifer Adgey, MD, FACC ,
Thomas R. Vrobel, MD, FACC ,
Stephen G. Ellis, MD, FACC*,
Karl-Ludwig Neuhaus, MD, FACC1,
Nadine Juran, RN*,
Thomas B. Ivanc, MS*,
E. Magnus Ohman, MD, FACC||,
John Strony, MD, FACC¶,
Michael Kitt, MD, FACC#,
Eric J. Topol, MD, FACC* for the INTRO AMI Investigators
* Cleveland Clinic Foundation, Cleveland, Ohio, USA
Staedtische Kliniken, Kassel, Germany
Royal Victoria Hospital, Belfast, Ireland
MetroHealth Medical Center, Cleveland, Ohio, USA
|| Duke Medical Center, Durham, North Carolina, USA
¶ Schering-Plough Research Institute, Kenilworth, New Jersey, USA
# COR Therapeutics, South San Francisco, California, USA
Manuscript received August 2, 2001;
revised manuscript received October 26, 2001,
accepted November 7, 2001.
* Reprint requests and correspondence: Dr. Sorin J. Brener, 9500 Euclid Ave., Desk F-25, Cleveland, Ohio 44195, USA breners{at}ccf.org
OBJECTIVES: This study was designed to test the hypothesis that eptifibatide and reduced-dose tissue plasminogen activator (t-PA) will enhance infarct artery patency at 60 min in patients with acute myocardial infarction (AMI).
BACKGROUND: Combination fibrin and platelet lysis improves epicardial and myocardial reperfusion in AMI.
METHODS: Patients were enrolled in a dose finding (Phase A, n = 344) followed by a dose confirmation (Phase B, n = 305) protocol. All patients received aspirin and weight-adjusted heparin and underwent angiography at 60 and 90 min. In Phase A, eptifibatide in a single or double bolus (30 min apart) of 180, 180/90 or 180/180 µg/kg followed by an infusion of 1.33 or 2.0 µg/kg per min was sequentially added to 25 or 50 mg of t-PA. In Phase B, patients were randomized to: 1) double-bolus eptifibatide 180/90 (30 min apart) and 1.33 µg/kg per min infusion with 50 mg t-PA (Group I); 2) 180/90 (10 min apart) and 2.0 µg/kg per min with 50 mg t-PA (Group II); or 3) full-dose, weight-adjusted t-PA (Group III).
RESULTS: In Phase A, the best rate of Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was achieved using 180/90/1.33 µg/kg per min eptifibatide with 50 mg t-PA: 65% and 78% at 60 and 90 min, respectively. In Phase B, the incidence of TIMI flow grade 3 at 60 min was 42%, 56% and 40%, for Groups I through III, respectively (p = 0.04, Group II vs. Group III). The median corrected TIMI frame count was 38, 33 and 50, respectively (p = 0.02). TIMI major bleeding was reported in 8%, 11% and 6%, respectively; intracranial hemorrhage occurred in 1%, 3% and 2% of patients (p > 0.5 for both). The incidences of death (4%, 5% and 7%), reinfarction or revascularization at 30 days were similar among the three treatment groups.
CONCLUSIONS: In comparison with standard t-PA regimen, double-bolus eptifibatide (10 min apart) with a 48-h infusion and half-dose t-PA (Group II) is associated with improved quality and speed of reperfusion. The safety profile of this therapy is similar to that of other combination regimens.
|
Abbreviations and Acronyms
| | GUSTO | | AMI | | acute myocardial infarction | | aPTT | | activated prothrombin time | | cTFC | | corrected TIMI frame count | | CK-MB | | creatine kinase-MB | | ECG | | electrocardiogram | | GP | | glycoprotein | | GUSTO | | Global Utilization To Open occluded coronary arteries | | ICH | | intracranial hemorrhage | | LAD | | left anterior descending artery | | TIMI | | Thrombolysis In Myocardial Infarction | | t-PA | | tissue plasminogen activator |
|
This article has been cited by other articles:

|
 |

|
 |
 
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
708S - 775S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Circulation,
December 19, 2006;
114(25):
2871 - 2891.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Circulation,
December 20, 2005;
112(25):
3855 - 3867.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Part 5: Acute Coronary Syndromes
Circulation,
November 29, 2005;
112(22_suppl):
III-55 - III-72.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol
Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials
JAMA,
April 13, 2005;
293(14):
1759 - 1765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Wiggins and S. Spinler
Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes
Journal of Pharmacy Practice,
October 1, 2004;
17(5):
347 - 369.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
549S - 575S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Goto, N. Tamura, and H. Ishida
Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions
J. Am. Coll. Cardiol.,
July 21, 2004;
44(2):
316 - 323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Antman and F. Van de Werf
Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction
Circulation,
June 1, 2004;
109(21):
2480 - 2486.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. S. Gurm, A. M. Lincoff, D. Lee, W. H. W. Tang, G. Jia, J. E. Booth, R. M. Califf, E. M. Ohman, F. Van de Werf, P. W. Armstrong, et al.
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial
J. Am. Coll. Cardiol.,
February 18, 2004;
43(4):
542 - 548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. W.A. Verheugt
Combining glycoprotein blockers with fibrinolysis: a bold stroke?
Eur. Heart J.,
October 2, 2003;
24(20):
1801 - 1803.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Eisenberg and S. Jamal
Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction
J. Am. Coll. Cardiol.,
July 2, 2003;
42(1):
1 - 6.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A Crouch, J. M Nappi, and K. I Cheang
Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome
Ann. Pharmacother.,
June 1, 2003;
37(6):
860 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano, M. T. Roe, R. A. Harrington, C. M. Gibson, U. Zeymer, F. Van de Werf, K. W. Baran, H.-P. Hobbach, L. H. Woodlief, K. L. Hannan, et al.
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial
J. Am. Coll. Cardiol.,
April 16, 2003;
41(8):
1251 - 1260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Kleiman
Combination therapy for acute myocardial infarction: Will it survive?
J. Am. Coll. Cardiol.,
April 16, 2003;
41(8):
1261 - 1263.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Inverso
Combination Glycoprotein IIb/IIIa Receptor Antagonists With Thrombolytics in Acute Myocardial Infarction
Journal of Pharmacy Practice,
August 1, 2002;
15(4):
344 - 355.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Van de Werf and D. S. Baim
Reperfusion for ST-Segment Elevation Myocardial Infarction: An Overview of Current Treatment Options
Circulation,
June 18, 2002;
105(24):
2813 - 2816.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Eptifibatide plus Low-Dose t-PA for Acute MI
Journal Watch Cardiology,
March 29, 2002;
2002(329):
3 - 3.
[Full Text]
|
 |
|
|